retatrutide ly3437943 triple agonist glp-1 gip glucagon Eli Lilly's shows promising weight loss results in phase 3 trial Retatrutide (LY3437943) | Triple GIP/GLP-1/Glucagon

Finally, we emphasize the advantages and disadvantages of bacterial carriers when used to treat cancer and their potential for clinical translation

The model uses practical inputs that can be explained and tracked, including diabetes prevalence and growth, treated patient share on injectables, average dose and persistence by therapy, country level reimbursement breadth, and typical list to net price behavior where relevant

When you're managing conditions like Type 2 Diabetes or PCOS alongside a GLP-1 medication, it's not just about the medication itself

GLP-1 medications like semaglutide (Ozempic, Wegovy) are not FDA-approved specifically for PCOS

For general maintenance or mild symptoms, once-daily dosing typically suffices and simplifies the protocol